Revolutionizing Cancer Treatment with Precision Nanotechnology
About Us
OnCuRNA is a preclinical-stage oncology company advancing the SANG platform, a nanohydrogel technology designed to optimize drug delivery to solid tumors and minimize the serious toxicities associated with current cancer treatments. Our proprietary nanohydrogel drug delivery platform outperforms traditional lipid-based nanoparticle systems, providing a more effective and precise approach to targeting tumors. With a focus on translational science, we aim to bring groundbreaking therapies from the lab to the clinic, improving outcomes for patients worldwide.
Our Technology
Next-Gen Drug Delivery Platform
At OnCuRNA, our novel nanohydrogel system (SANGs) enhances the delivery of therapeutic payloads to solid tumors, offering unprecedented control over drug release, targeting, and efficacy. Our SANGs platform is agnostic to the solid tumor type and to drug payload, making it well suited across multiple oncological indications. Currently, our technology has demonstrated success in four solid tumor models and advanced stage metastasis models, offering hope for more effective cancer treatment solutions.
Key Features
Targeted delivery to solid tumors
Broad compatibility with a variety of therapeutic payloads
Enhanced primary tumor and metastasis penetration and retention
Our Mission
Pioneering the Future of Cancer Treatment
OnCuRNA’s mission is to revolutionize how cancer is treated, by enabling highly specific delivery of therapies to solid tumors. OnCuRNA is dedicated to improving the quality of life for individuals diagnosed with cancer by bringing our innovative drug delivery platform to the clinic. We combine cutting-edge research with a patient-focused approach to develop new cancer therapies that are both effective and accessible.
Our Pipeline
Exploring New Horizons in Cancer Therapy
The flexibility of our innovative SANGs platform enables a broad developmental pipeline with multiple oncological indications and different therapeutic agents, maximizes the potential for translational success. We are actively completing our remaining IND-enabling studies with our sights set on first-in-human trials and advancing preclinical studies across a variety of additional solid tumors indications and are credentialing additional therapeutic targets.
Join Us in the Fight Against Cancer
Team
OnCuRNA is founded by a team of world-class scientists with multi-disciplinary skills in basic science, synthetic chemistry, preclinical research, drug development, and commercialization of therapeutics. We have collectively over 100 years of experience in science and drug development.
Partner with Us
Collaborating for a Cure
OnCuRNA welcomes partnering opportunities with academic and industry groups who share our vision for innovation and patient-centered care. OnCuRNA has developed a broad IP portfolio focused on the use of nanohydrogels for oncological indications with a particular interest in exploring delivery of small molecules, and macromolecules such as nucleic acids and peptides to solid tumors. We invite you to explore partnership opportunities with us to advance cancer treatment.